πŸ‡ΊπŸ‡Έ FDA
Patent

US 11559567

Dosage regimen for pegylated interferon

granted A61KA61K38/21A61K38/212

Quick answer

US patent 11559567 (Dosage regimen for pegylated interferon) held by PHARMAESSENTIA CORPORATION expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PHARMAESSENTIA CORPORATION
Grant date
Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/21, A61K38/212, A61K47/60, A61P